Review articleTherapeutic possibilities of drugs encapsulated in erythrocytes
References (39)
- et al.
Polymerized micelles and their use as adjuvants in immunology
J. Pharm. Sci.
(1976) - et al.
The isolation of a suppressible nonsence mutant in mammalian cells
Cell
(1977) - et al.
A dialysis procedure for loading erythrocytes with enzymes and lipids
Biochem. Biophys. Acta
(1977) - et al.
An erythrocyte encapsulator dialyser used in preparing large quantities of erythrocyte ghosts and encapsulation of a pesticide in erythrocyte ghosts
Anal. Biochem.
(1980) - et al.
The influence of amphotericin-B on the permeability of mammalian erythrocytes to non-electrolytes, anions and cations
Biochim. Biophys. Acta
(1973) - et al.
Clinical trial of desferrioxamine entrapped in red cell ghosts
Lancet
(1980) - et al.
Adenosine triphosphate and maintenance of shape of the human red blood cell
Nature (Lond.)
(1960) - et al.
The use of corticosteroids encapsulated in erythrocytes in the treatment of adjuvant induced arthritis in the rat
Biochem. Pharmacol.
(1983) - et al.
Human erythrocyte fractionation in Percoll density gradients
Clin. Chim. Acta
(1979) - et al.
Asparaginase entrapped in red blood cells: action and survival
Science
(1976)
Prevention of haemolysis by bivalent metal ions during virus-induced fusion of erythrocytes with Ehrlich ascites tumour cells
FEBS Lett.
The effect of encapsulation in red blood cells on the distribution of methotrexate in mice
J. Clin. Chem. Clin. Biochem.
Use of enzyme loaded erythrocytes in the correction of arginase-deficient erythrocytes in familial hyperargininemia
Clin. Chem.
Circulating asparaginase encapsulated in erythrocytes depletes plasma asparagine and glutamine levels in vivo
J. Pharm. Pharmacol.
Pharmaceutical possibilities of intact erythrocytes as drug carriers
J. Pharm. Pharmacol.
Enzyme replacement therapy in Gauchers disease. Preliminary clinical trial of a new enzyme preparation
Artificial Cells
Glutaraldehyde treated carrier erythrocytes for organ targeting of methotrexate in dogs
Am. J. Vet. Res.
Albumin conjugates of fungal toxins and inhibitors of DNA synthesis
Cited by (46)
Resealed erythrocytes: Towards a novel approach for anticancer therapy
2021, Journal of the Indian Chemical SocietyCitation Excerpt :Later, either lyophilization or sintered glass filtration could be used to dehydrate the cell suspension. Lewis et al. reported that the powdered resultant product can be stored for about a month without losing any of its carrier properties [23]. However, it was found that a significant amount of membrane stabilizing agents remains bound to the carrier cells, hence, the cell survival time in circulation is reduced [86,87].
Resealed erythrocytes (RBCs) and their biomedical application
2020, The Future of Pharmaceutical Product Development and ResearchMagnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer
2018, Journal of Controlled ReleaseCitation Excerpt :Moreover, erythrocyte-based DDS have the ability to protect the loaded drug from degradation, can greatly reduce the possibility of acquiring a severe immunologic reaction when autologous erythrocytes are used and can act as bioreactors transforming the pro-drug in drug, due to their stable metabolic/enzymatic system [16]. Consequently, they can also reduce possible cytotoxic effects of the carried compounds [17] and can improve their pharmacokinetics and pharmacodynamics. In addition, erythrocytes can be magnetized, by entrapping spmNPs within them, thus making such DDS responsive to an external magnetic field [18].
Engineering erythrocytes as a novel carrier for the targeted delivery of the anticancer drug paclitaxel
2014, Saudi Pharmaceutical JournalCitation Excerpt :Therefore, controlling the life-span of carrier erythrocytes can be an effective method to achieve the desired profile of delivery, i.e., to obtain a suitable RES-targeting delivery system. PTX diffused through the lipid bilayer into the plasma, as observed for lipophilic drugs (Lewis and Alpar, 1984). The drug apparently diffused readily because cell membrane lysis was not essential for the release of PTX from loaded erythrocytes.
Layer-by-layer microcapsules templated on erythrocyte ghost carriers
2011, International Journal of PharmaceuticsCitation Excerpt :The kinetics of the drug release from erythrocyte carriers depends on the size and polarity of the encapsulated agents. In general three different patterns of drug release can be observed: (1) the drug release occurs by rapid diffusion through the membrane for lipophilic drugs such as primaquin (Talwar and Jain, 1992a), methotrexate (Lewis and Alpar, 1984), (2) the drug release occurs by cell lysis for polar drugs such as enalaprilat (Hamidi et al., 2001) or gentamicin (Eichler et al., 1986), and (3) the release profile is intermediate between the first two patterns, as observed for erythropoietin (Garín et al., 1996) and isoniazid (Jain et al., 1995). Among the different strategies to control the release of drugs from erythrocytes, crosslinking with glutaraldehyde seems to be one of the most successful to date (Talwar and Jain, 1992b).
Encapsulation of Concentrated Protein Into Erythrocyte Porated by Continuous-Wave Ultrasound
2008, Ultrasound in Medicine and BiologyCitation Excerpt :Several physical methods have been reported for encapsulation of therapeutic water-soluble drugs, peptides or proteins in erythrocytes (carrier erythrocytes) (Hamidi and Tajerzadeh 2003; Lewis and Alpar 1984; Tyrrel and Ryman 1976), as well as for a physical transfection effect (Kodama et al. 2006).